Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

CVS HEALTH CORPORATION (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

CVS Health : Revenue Rises as It Pursues Aetna

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/06/2017 | 02:11pm CEST
By Cara Lombardo 

Stronger pharmacy sales boosted CVS Health Corp.'s revenue in its latest quarter as the drugstore chain weighs a purchase of health insurer Aetna Inc., a move that would bolster its prescription business.

CVS's third-quarter revenue rose 3.5% to $46.2 billion, matching what analysts polled by Thomson Reuters expected.

The Wall Street Journal reported last month that the drugstore giant is in talks to buy Aetna for $66 billion, according to people familiar with the matter, following a six-month hunt for a deal partner. The move would strengthen CVS's position in negotiations with drugmakers, and analysts are likely to question company executives about the potential tie-up on a Monday earnings call.

People familiar with the discussions have said it could take until the end of the year to solidify a deal, if it happens.

In its latest quarter, sales in CVS's pharmacy-services segment increased 8.1% to $32.9 billion, driven by growth in pharmacy network claims and specialty pharmacy volume. Retail segment sales, meanwhile, slipped 2.7% to $19.6 billion, hurt by falling same-store sales.

The company also recorded $55 million in expenses related to the recent string of hurricanes, with most of it impacting the retail segment.

Overall for the quarter, CVS reported a profit of $1.3 billion, or $1.26 a share, compared with $1.5 billion, or $1.43 a share, a year ago.

Excluding one-time items, the Woonsocket, R.I.-based company earned $1.50 a share, compared with $1.64 a year ago. Analysts had expected adjusted earnings per share of $1.48 on net income of $1.5 billion.

The company also narrowed its full-year earnings guidance and raised the midpoint. It now expects adjusted earnings of $5.87 to $5.91. It previously guided a range of $5.83 to $5.93.

CVS shares, down 12% this year, rose less than 1% premarket on low volume.

Write to Cara Lombardo at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
AETNA -1.48% 187.22 Delayed Quote.3.79%
CVS HEALTH CORPORATION -1.33% 65.26 Delayed Quote.-9.99%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORPORATION
07/19CVS HEALTH : State announces corporate partners for Woonsocket-based job trainin..
AQ
07/18CVS HEALTH : Schofield added to CVS' transition program
AQ
07/18CVS HEALTH : Expands Commitment to Veterans Transitioning to Civilian Life
PR
07/18CVS HEALTH : AG Steve Marshall, CVS Health Announce Safe Drug Disposal Program i..
AQ
07/18CVS HEALTH : Raimondo Bringing New Job Training Center to Woonsocket
AQ
07/17CVS HEALTH : Foundation awards $60,000 in grants
AQ
07/17CVS HEALTH : Empirical Financial Services Cut Its Apple (AAPL) Stake by $6.26 Mi..
AQ
07/16CVS HEALTH : 2 CVS workers lose jobs after cops called on black customer
AQ
07/16CVS HEALTH : Responds to Request for Information on Trump Administration's Bluep..
PR
07/16CORRECTION : CVS-Black Customer story
AQ
More news
News from SeekingAlpha
07/20QUARTERLY REVIEW OF DIVGRO : Q2 2018 
07/19My Dividend Growth Portfolio - Q2 2018 Summary 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/19Innovus Pharma inks deal with CVS Pharmacy to sell Androferti to increase spe.. 
07/18FDA committed to easing approval path for biosimilars 
Financials ($)
Sales 2018 189 B
EBIT 2018 10 003 M
Net income 2018 5 433 M
Debt 2018 19 470 M
Yield 2018 3,23%
P/E ratio 2018 12,60
P/E ratio 2019 9,93
EV / Sales 2018 0,46x
EV / Sales 2019 0,43x
Capitalization 67 241 M
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 85,4 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORPORATION-9.99%67 241
WALGREENS BOOTS ALLIANCE-10.52%64 437
EXPRESS SCRIPTS HOLDING CO3.91%43 101
MCKESSON CORPORATION-14.78%27 000
AMERISOURCEBERGEN-7.75%18 806
CARDINAL HEALTH-20.35%15 224